Putney Receives FDA Approval for Tiletamine-Zolazepam, Generic of Telazol®

Portland, ME—April 6, 2015—Putney, Inc., a rapidly growing pet pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has received FDA Center for Veterinary Medicine (CVM) approval for its Tiletamine-Zolazepam (tiletamine HCl and zolazepam HCl) injectable, the generic of Telazol®. This is Putney's sixth FDA approval in seven months, following closely the FDA approvals for Putney's Carprofen Chewable Tablets (generic of Rimadyl® Chewable Tablets), Putney's Dexmedetomidine HCl Sterile Injectable Solution (generic of Dexdomitor®), Putney's Carprofen Sterile Injectable Solution (generic of Rimadyl® Injectable), and Putney's Enrofloxacin Antibacterial Injectable Solution (generic of Baytril® Antibacterial Injectable Solution). "Putney is the first company to earn FDA approval for the manufacture of generic tiletamine HCl and zolazepam HCl, a very complex, sterile drug. This is another major accomplishment by our R&D team and a great addition to our product portfolio," says Dr. Anthony Lucas BVMS, PhD, Putney's Senior Vice President of Scientific and Medical Affairs.

Jean Hoffman, Putney president and CEO, says commercialization of Putney's recent FDA approvals will accelerate Putney's revenue growth in 2015 and beyond. "Putney is developing first-to-market, commercially relevant veterinary generics. These are the affordable pet medicines that veterinarians want but have never had access to before," says Hoffman. She notes that Putney's impressive 2014 revenue growth of 45% was largely driven by market penetration of existing products.

Putney is planning commercial launch of its Tiletamine-Zolazepam for June 2015.

 

Telazol® is a registered trademark of Zoetis LLC.

Rimadyl® is a registered trademark of Zoetis LLC.

Dexdomitor® is a registered trademark of Orion Corporation.

Baytril® is a registered trademark of Bayer Aktiengesellschaft.

 

About Putney

Putney is a pharmaceutical company committed to providing high quality, cost-effective generic medicines for pets. Putney's reliable supply of affordable drug options empowers veterinarians, allowing them to provide the best possible medicine at the best possible price, nd supports pet owners, helping them afford to comply with veterinary recommendations. Putney's ongoing investment in research and development is focused on creating the next generation of generic veterinary products based on inputs from companion animal veterinarians and its industry partners. Learn more at www.putneyvet.com.

 

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…